Relevance of antithrombin prescriptions at Strasbourg University Hospitals
Official title: Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
Run by University Hospital, Strasbourg, France · NCT07276074 · Data updated 2026-11-12
This project will see if giving antithrombin to adults in intensive care or during surgery at Strasbourg University Hospitals is being used appropriately and linked to effective anticoagulation with heparin.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | December 18, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | December 10, 2025 |
| Trial ID | NCT07276074 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18 or older) who received at least one dose of antithrombin in an intensive care unit or operating room at Strasbourg University Hospitals during the specified 2022–2023 period are the focus of this review.
✕Probably not a fit
People under 18, patients who did not receive antithrombin, those treated outside Strasbourg University Hospitals or outside the 2022–2023 window, and anyone who opted out of data reuse will not be included and will not benefit directly from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational review of adult patients who received antithrombin at Strasbourg University Hospitals between January 1, 2022 and December 31, 2023. Investigators will extract clinical records to describe why antithrombin was given (for example during ECMO, RRT, or cardiopulmonary bypass), dosing and timing, and available laboratory monitoring. The analysis will look for patterns suggesting inappropriate use or associations with inadequate anticoagulation where antithrombin may have a role. No experimental treatments or changes to care are involved and patients who objected to reuse of their data are excluded.
Why it matters
Potential benefit: If successful, the work could help optimize when and how antithrombin is given, reducing ineffective anticoagulation and improving patient safety during extracorporeal support or surgery.
How similar studies have gone: Other observational studies have documented antithrombin deficiency during extracorporeal therapies, but randomized trials of routine antithrombin replacement have not demonstrated consistent outcome benefits, so routine replacement remains somewhat unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult subject (≥18 years old) * Female and male * Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023. Exclusion Criteria: * Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes * Minor subject
Where it's running
-
Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Xavier DELABRANCHE, MD
- Email: xavier.delabranche@chru-strasbourg.fr
- Phone: 33 3 69 55 09 36
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.